208 related articles for article (PubMed ID: 26061636)
1. Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.
Szwarc MM; Kommagani R; Jacob AP; Dougall WC; Ittmann MM; Lydon JP
PLoS One; 2015; 10(6):e0128467. PubMed ID: 26061636
[TBL] [Abstract][Full Text] [Related]
2. Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland.
Hai L; Szwarc MM; Lonard DM; Rajapakshe K; Perera D; Coarfa C; Ittmann M; Fernandez-Valdivia R; Lydon JP
Cytokine; 2019 Nov; 123():154745. PubMed ID: 31226438
[TBL] [Abstract][Full Text] [Related]
3. RANK and RANK Ligand Expression in Parotid Gland Carcinomas.
Franchi A; Taverna C; Simoni A; Pepi M; Mannelli G; Fasolati M; Gallo O
Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):478-482. PubMed ID: 29494398
[TBL] [Abstract][Full Text] [Related]
4. RANK and RANKL Expression in Salivary Gland Tumors.
Aslan F; Küçük Ü
Ear Nose Throat J; 2020 Aug; 99(7):475-480. PubMed ID: 32525717
[TBL] [Abstract][Full Text] [Related]
5. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
6. RANKL inhibition: a promising novel strategy for breast cancer treatment.
González-Suárez E
Clin Transl Oncol; 2011 Apr; 13(4):222-8. PubMed ID: 21493182
[TBL] [Abstract][Full Text] [Related]
7. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
8. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells.
Beristain AG; Narala SR; Di Grappa MA; Khokha R
J Cell Sci; 2012 Feb; 125(Pt 4):943-55. PubMed ID: 22421365
[TBL] [Abstract][Full Text] [Related]
9. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse.
Fernandez-Valdivia R; Mukherjee A; Ying Y; Li J; Paquet M; DeMayo FJ; Lydon JP
Dev Biol; 2009 Apr; 328(1):127-39. PubMed ID: 19298785
[TBL] [Abstract][Full Text] [Related]
10. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
11. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.
Simatou A; Sarantis P; Koustas E; Papavassiliou AG; Karamouzis MV
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066388
[TBL] [Abstract][Full Text] [Related]
12. RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain.
Wang K; Hackney JR; Siegal GP; Wei S
Clin Breast Cancer; 2020 Oct; 20(5):e569-e575. PubMed ID: 32381383
[TBL] [Abstract][Full Text] [Related]
13. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
14. RANKL Signaling and ErbB Receptors in Breast Carcinogenesis.
Zoi I; Karamouzis MV; Adamopoulos C; Papavassiliou AG
Trends Mol Med; 2016 Oct; 22(10):839-850. PubMed ID: 27567286
[TBL] [Abstract][Full Text] [Related]
15. The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.
Monzó-Miralles A; Martín-González V; Smith-Ballester S; Iglesias-Miguel V; Cano A
Adv Clin Exp Med; 2021 Sep; 30(9):879-883. PubMed ID: 34435475
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.
Marley K; Bracha S; Seguin B
Exp Cell Res; 2015 Oct; 338(1):32-8. PubMed ID: 26254896
[TBL] [Abstract][Full Text] [Related]
17. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
18. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini.
Gonzalez-Suarez E; Branstetter D; Armstrong A; Dinh H; Blumberg H; Dougall WC
Mol Cell Biol; 2007 Feb; 27(4):1442-54. PubMed ID: 17145767
[TBL] [Abstract][Full Text] [Related]
19. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
[TBL] [Abstract][Full Text] [Related]
20. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
